Investigational drug · Phase 2
TYK-01054
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor Malignancies, Malignant Mesothelioma (MM).
Phase 2Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TYK-01054"
First trial start
2026
Jan 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TYK-01054", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor Malignancies
- Malignant Mesothelioma (MM)
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TYK-01054" as an intervention, largest first.
- Study of TYK-01054 Capsules in Patients With Advanced Solid TumorsNot yet recruiting
TYK Medicines, IncIndustry
NCT07282873 · 219 participants (planned) · Start Jan 1, 2026 · Primary completion Jan 2028
Drug: TYK-01054 · For: Solid Tumor Malignancies; Malignant Mesothelioma (MM)
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Solid Tumor Malignancies
- FG-M108M108Phase 32 trials
FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Pancreatic Cancer
- FG-B901Phase 22 trials
FutureGen Biopharmaceutical (Beijing) Co., Ltd · Claudin 18.2, Solid Tumor Malignancies, Solid Tumor
- CP-383Phase 21 trial
Tasca Therapeutics · Solid Tumor Malignancies, Colorectal Carcinoma, Small Cell Lung Cancer ( SCLC )
- VTRU200Phase 21 trial
Vitruviae · Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL), High Risk Myelodysplastic Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.